

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1 (Currently Amended). A method of treating a patient, which comprises:

selecting a patient with immune hyperactivity ~~in need of immune suppression~~; and
administering to said patient an effective amount of an IL-27R agonist, wherein said agonist is selected from the group consisting of IL-27, an active fragment of IL-27, an agonistic antibody, and a IL-27R binding antibody fragment that enhances IL-27R activity.

2-10 (Cancelled).

11 (Currently Amended). The method of claim 74 [[6]], wherein said T-helper cell is Th1.

12 (Currently Amended). The method of claim 74 [[6]], wherein said T-helper cell is Th2.

13-19 (Cancelled).

20 (Currently Amended). The method of claim 1 [[19]], wherein said patient has an immune disorder ~~is~~ selected from the group consisting of autoimmune disorders, hypersensitivity disorders, allergies, and asthma.

21 (Previously Presented). The method of claim 20, wherein said immune disorder is selected from the group consisting of: acute pancreatitis; Addison's disease; alcohol-induced liver injury; Alzheimer's disease; amyotrophic lateral sclerosis; asthma; pulmonary diseases; atherosclerosis; autoimmune vasculitis; autoimmune hepatitis-induced hepatic injury; cachexia/anorexia; AIDS-induced cachexia; multiple myeloma; leukemia; myelogenous leukemia; tumor metastasis; chronic fatigue syndrome; congestive heart failure; coronary

restenosis; myocardial dysfunction; a coronary artery bypass graft associated condition; juvenile onset Type 1 diabetes; diabetes mellitus insulin resistance; endometriosis; endometritis; endometriosis/endometritis related condition; epididymitis; erythropoietin resistance; fever; fibromyalgia; analgesia; glomerulonephritis; graft versus host disease/transplant rejection; Graves' disease; Guillain-Barre syndrome; Hashimoto's disease; hemolytic anemia; hemorrhagic shock; hyperalgesia; inflammatory bowel disease; ulcerative colitis; Crohn's disease; an inflammatory condition of a joint; rheumatic diseases; osteoarthritis; rheumatoid arthritis; juvenile (rheumatoid) arthritis; seronegative polyarthritis; ankylosing spondylitis; Reiter's syndrome; reactive arthritis; Still's disease; enteropathic arthritis; polymyositis; dermatomyositis; scleroderma; systemic sclerosis; cerebral vasculitis; Lyme disease; staphylococcal induced arthritis; Sjogren's syndrome; rheumatic fever; polychondritis; polymyalgia rheumatica; giant cell arteritis; inflammatory eye disease; corneal transplant associated inflammatory eye disease; inflammatory bowel disease; Kawasaki's disease; lung disease; lupus nephritis; multiple sclerosis; myasthenia gravis; myopathicneuroinflammatory disease; uveitis; osteoporosis; Parkinson's disease; pemphigus; Pityriasis rubra pilaris; prostatitis; a prostatitis related conditions; psoriasis; a psoriasis related condition; psoriatic arthritis; pulmonary fibrosis; reperfusion injury; sarcoidosis; scleroderma; septic shock; sleep disturbance; spondyloarthropathies; systemic lupus erythematosus; temporal mandibular joint disease; thyroiditis; tissue transplantation; an inflammatory condition resulting from strain; an inflammatory condition resulting from sprain; an inflammatory condition resulting from cartilage damage; an inflammatory condition resulting from trauma; an inflammatory condition resulting from orthopedic surgery; an inflammatory condition resulting from infection; transplant rejection; and vasculitis.

22 (Cancelled).

23 (Cancelled).

24 (Previously Presented). A method for suppressing a T-helper cell mediated immune response independent of polarization of the immune response in a patient in need thereof,

which comprises administering to said patient an effective amount of an IL-27R agonist, wherein said agonist is selected from the group consisting of IL-27, an active fragment of IL-27, an agonistic antibody, and a IL-27R binding antibody fragment that enhances IL-27R activity.

25 (Previously Presented). The method of claim 24, wherein said T-helper cell is Th1.

26 (Previously Presented). The method of claim 24, wherein said T-helper cell is Th2.

27 – 73 (Cancelled).

74 (New). The method of claim 1, wherein the immune hyperactivity is T-helper cell mediated immune hyperactivity.

75 (New). The method of claim 1, wherein the immune hyperactivity is interferon- γ mediated immune hyperactivity.